(MedPage Today) — Bevacizumab (Avastin) combined with erlotinib (Tarceva) showed activity in patients with hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated or sporadic papillary renal cell carcinoma (RCC), a phase II trial suggested…
Source link : https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/116149
Author :
Publish date : 2025-06-18 21:00:00
Copyright for syndicated content belongs to the linked Source.
